| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 02/15/2006 | CN1241944C Antibody againts 'alpha'-chain of human interleukin 5 receptor |
| 02/15/2006 | CN1241940C Novel collagen-like protein CLAC, Precursor thereof and genes encoding the same |
| 02/14/2006 | US6998514 Murine expression of a human IgA lambda locus |
| 02/14/2006 | US6998513 Human inflammatory breast carcinoma xenograft capable of lymphovascular invasion and methods for its use |
| 02/14/2006 | US6998473 isolated polynucleotide molecules which encode the isoforms ; methods of screening compounds for vitamin D receptor (VDR) agonists and/or antagonists |
| 02/14/2006 | US6998470 by using diafiltration, solid phase extraction and immunoaffinity techniques |
| 02/14/2006 | US6998469 for treating thrombosis and other vascular diseases |
| 02/14/2006 | US6998468 Anti-C2/C2a inhibitors of complement activation |
| 02/14/2006 | US6998467 diagnosing for and detection of carriers of the gene, Alzheimer's Disease diagnosis, gene therapy using recombinant technologies and therapy using the information derived from the DNA, protein, and the metabolic function of the protein |
| 02/14/2006 | US6998260 DNA expression construct comprising, in 5' to 3' order: a promoter operationally linked to a secretion signal sequence, the secretion signal sequence operationally-linked to a DNA sequence encoding a proteolytic tryptase having active site mutation |
| 02/14/2006 | US6998253 polypeptide of interest is cleared from kidney and does not contain a Fc region of an IgG, which variant comprises a salvage receptor binding epitope of an Fc region of an IgG, and which variant has a longer in vivo half-life than the polypeptide |
| 02/14/2006 | US6998245 Serine protease BSSP5 |
| 02/14/2006 | US6998244 contacting a cell transformed or transfected with an expression vector capable of expressing 5-HT4 receptor with a compound in presence of a ligand, monitoring CAMP formation in the cell, a change indicates compund as an antagonist or agonist |
| 02/14/2006 | US6998242 Method of diagnosing metabolic bone diseases |
| 02/14/2006 | US6998239 contacting an isolated or recombinant CCX CKR polypeptide or, a fragment or variant, and the chemokine in the presence of a test compound, comparing the level of binding of the chemokine and the polypeptide |
| 02/14/2006 | US6998238 Method for determining MIF content |
| 02/14/2006 | US6998237 GD3 peptide mimics |
| 02/14/2006 | US6998124 Erythropoietin receptor antibodies |
| 02/14/2006 | US6998123 interleukins (IL-11); fibronectins; glycoproteins |
| 02/14/2006 | US6998108 Antibodies to p30 polypeptides and methods making and using same |
| 02/09/2006 | WO2006015373A2 Antibodies to dkk-1 |
| 02/09/2006 | WO2006015371A2 Humanized anti-cmet antagonists |
| 02/09/2006 | WO2006015079A2 Erm family binding agents and their use in diagnosis and treatment of proliferative conditions |
| 02/09/2006 | WO2006014903A2 Compositions and methods of use for adam12 antagonists in treating disease |
| 02/09/2006 | WO2006014729A2 Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| 02/09/2006 | WO2006014726A2 Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
| 02/09/2006 | WO2006014683A2 Immunoglobulins comprising predominantly a gal2glcnac2man3glcnac2 glycoform |
| 02/09/2006 | WO2006014679A1 Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
| 02/09/2006 | WO2006014505A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 02/09/2006 | WO2006014477A1 HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD |
| 02/09/2006 | WO2006014335A2 Compositions and methods for treatment of non-hodgkin’s lymphoma |
| 02/09/2006 | WO2006013904A1 Medicinal composition containing meltrin antagonist |
| 02/09/2006 | WO2006013474A2 Ppgalnac-t6 mrna or peptide as a new marker for detection cancer cells |
| 02/09/2006 | WO2006013472A2 Novel anti-igf-ir antibodies and uses thereof |
| 02/09/2006 | WO2006013334A1 Hai-1 and hai-2 in cancer therapy |
| 02/09/2006 | WO2006013107A1 Il-17 antagonistic antibodies |
| 02/09/2006 | WO2006013087A1 Human monoclonal antibodies against human il-4 |
| 02/09/2006 | WO2006012949A1 Method of diagnosing lawsonia intracellularis |
| 02/09/2006 | WO2005123778A3 Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
| 02/09/2006 | WO2005123129A3 Methods of redistributing apical target antigens to detect and treat cellular proliferative disease |
| 02/09/2006 | WO2005121797A3 Screening method using antibody heavy chains |
| 02/09/2006 | WO2005118864A3 Antibodies and related molecules that bind to psca proteins |
| 02/09/2006 | WO2005113786A3 Diagnostics and therapeutics for diseases associated with chymase (cma1) |
| 02/09/2006 | WO2005113000A3 Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
| 02/09/2006 | WO2005111621A3 Molecular scaffolds for hiv-1 epitopes |
| 02/09/2006 | WO2005111083A3 Antibodies specific for glycoprotein vi and methods of producing these antibodies |
| 02/09/2006 | WO2005110479A3 Treatments for pancreatic cancer |
| 02/09/2006 | WO2005059106A3 Interferon alpha antibodies and their uses |
| 02/09/2006 | WO2005053604A3 Antibodies specific for cancer associated antigen sm5-1 and uses thereof |
| 02/09/2006 | WO2005016381A3 Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah |
| 02/09/2006 | WO2004056983A3 Metalloprotease proteins |
| 02/09/2006 | WO2002097110A3 TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF |
| 02/09/2006 | WO2002088316A3 G-protein coupled receptors |
| 02/09/2006 | US20060030696 Protein a chromatography |
| 02/09/2006 | US20060030695 Platelet-derived growth factor-D; anticarcinogenic agents, angiogenesis inhibition; tissue-targeted therapy; immunoassays; cancer diagnosis |
| 02/09/2006 | US20060030694 Antitumor agents; fusion protien increases biological half life |
| 02/09/2006 | US20060030527 Rage fusion proteins and methods of use |
| 02/09/2006 | US20060030524 Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
| 02/09/2006 | US20060030019 HDAC9 polypeptides and polynucleotides and uses thereof |
| 02/09/2006 | US20060030015 Novel process for producing antibody enzyme, novel antibody enzyme and utilization thereof |
| 02/09/2006 | US20060030005 C3b/C4b complement receptor-like molecules and uses thereof |
| 02/09/2006 | US20060030003 Composition and method for introduction of RNA interference sequences into targeted cells and tissues |
| 02/09/2006 | US20060030002 Isoforms of the human Vitamin D receptor |
| 02/09/2006 | US20060030000 Growth factor binding constructs materials and methods |
| 02/09/2006 | US20060029998 Codes with nucleic acids; antiinflammatory agents; immunomodulation |
| 02/09/2006 | US20060029990 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity |
| 02/09/2006 | US20060029986 Prevention and treatment of cardiovascular pathologies |
| 02/09/2006 | US20060029984 PSP94 diagnostic reagents and assays |
| 02/09/2006 | US20060029981 monoclonal antibody which specifically binds to an amino acid sequence of islet neogenesis associated protein (INGAP), used in competitive binding assays for quantitation of INGAP in biological samples |
| 02/09/2006 | US20060029966 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/09/2006 | US20060029964 Eating disorders; measuring obesity receptor (ObR) gene expression by detecting mRNA transcripts |
| 02/09/2006 | US20060029963 Isolated from Bacillus substilus; solid phase synthesis; reverse transcription; immunogens; transfected cells |
| 02/09/2006 | US20060029945 Novel full length cDNA |
| 02/09/2006 | US20060029940 Prostate stem cell antigen (PSCA) variants and subsequences thereof |
| 02/09/2006 | US20060029928 Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (prrsv), proteins encoded by the polynucleic acids, vaccines based on the proteins and/or polynucleic acids, a method of protecting a pig from a prrsv and a method of detecting a |
| 02/09/2006 | US20060029621 Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
| 02/09/2006 | US20060029611 Prevention and treatment of amyloidogenic disease |
| 02/09/2006 | US20060029609 administering drug biological conjugates used for the diagnosis, prophylaxis, or treatment of nervous system disorders or lysosomal storage diseases; drug delivery; blood brain barriers |
| 02/09/2006 | US20060029608 Immunization against clostridium difficile disease |
| 02/09/2006 | US20060029607 Methods and compositions for modulating tumor growth |
| 02/09/2006 | US20060029606 Insulin-like growth factor (IGF); peptide of given sequence; administered with co-agent such as doxorubicin, paclitaxel, methotrexate, tamoxifen, cyclophosphamide, vincristine, etoposide, 5-fluorouracil; anticarcinogen |
| 02/09/2006 | US20060029605 Use of ErbB receptor ligands in treating diabetes |
| 02/09/2006 | US20060029604 Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
| 02/09/2006 | US20060029603 Immunoglobulins |
| 02/09/2006 | US20060029602 secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner |
| 02/09/2006 | US20060029601 isolated human monoclonal antibodies or antigen binding portion, that bind to IFNAR-1, capable of blocking the action of type I interferons; use in the treatment of immune mediated disorders, including autoimmune disorders, transplant rejection and Graft Versus Host Disease (GVHD) |
| 02/09/2006 | US20060029599 Lyophilizing an aqueous formulation comprising a high concentration, 50 mg/ml or more of an immunoglobulin IgG antibody, in particular, daclizumab, in 5-25 mM histidine buffer, having pH 5.5-6.5, 0.005%-0.03% polysorbate, and sucrose |
| 02/09/2006 | US20060029597 IgA antibody protein as a cytotoxic drug |
| 02/09/2006 | US20060029595 Methods of using human receptor protein 4-1BB |
| 02/09/2006 | US20060029594 Interleukins (IL-5); for treating conditions associated with excess eosinophil production (such as chronic eosinophilic pneumonia, allergic bronchopulmonary aspergillosis, coeliac disease and/or gastroenteritis) |
| 02/09/2006 | US20060029593 Immunoglobulins having complementarity determining regions, heavy and light chain variable regions from humans that specifically bind to an antigen with affinity, used for in vivo therapy and diagnosis |
| 02/09/2006 | US20060029547 Generating prion specific immunoglobulin for use in diagnosis, prevention and treatment of neurodegenerative disorders |
| 02/09/2006 | DE102004031579A1 Peptide zur Inhibition der Interaktion von Proteinkinase A und Proteinkinase A-Ankerproteinen Peptides to inhibit the interaction of protein kinase A and protein kinase A anchoring proteins |
| 02/09/2006 | DE10002895B4 Koimmobilisierung mehrerer chemischer Spezies Co-immobilization of multiple chemical species |
| 02/09/2006 | CA2855056A1 A method of treating cancer comprising a vegf-b antagonist |
| 02/09/2006 | CA2576093A1 Pharmaceutical compostion containing meltrin antagonist |
| 02/09/2006 | CA2576037A1 Method of producing glycoprotein composition |
| 02/09/2006 | CA2575986A1 Method of assuming drug sensitivity to cdk4 inhibitor |
| 02/09/2006 | CA2575901A1 A method of treating cancer comprising a vegf-b antagonist |
| 02/09/2006 | CA2575606A1 Hai-1 and hai-2 in cancer therapy |